MindBio nominated for prestigious awards including
Company of the Year and LSD Company of the Year
MindBio Co-Founder Justin Hanka nominated
for two awards: Entrepreneur of the Year and Innovator of the Year
Vancouver, British Columbia – TheNewswire - September 22, 2022 – Blackhawk Growth Corp. (CSE:BLR); (Frankfurt:0JJ) (the “Company” or “Blackhawk”) is pleased to report that its subsidiary, MindBio Therapeutics (“MindBio”), and its Co-Founder Justin Hanka, have been nominated for a number of annual awards by global industry peers in the annual Microdose Awards.
Investors can vote for MindBio and Co-Founder Justin Hanka here
MindBio has been nominated in the category of Company of the Year alongside industry leaders Cybin, Dr. Bronner’s, Microdose Therapeutics and Psilera. MindBio is also nominated in the category for LSD Company of the Year alongside Beckley Psytech, BetterLife Pharma, MindMed and Psygen.
MindBio’s Co-Founder Justin Hanka has been nominated for Entrepreneur of the Year alongside industry leaders Christian Angermayer, David Champion, Iri Selkirk and Chris Witowski.
Mr Hanka has also been nominated in the category of Innovator of the Year alongside industry leaders Najla Guthrie, Dr. Darryl Hudson, Lars Christian Wilde and Jacki Von Salm.
The awards will be presented at the upcoming Wonderland Convention in Miami in November.
MindBio is also pleased to announce that preparations are well underway for the start of their Phase 2 Clinical trials and further announcements will be made after the presentation and reveal of data from their Phase 1 LSD Microdosing Clinical Trials in 80 healthy subjects.
“MindBio is leading the way in psychedelic microdosing clinical trials. With the recent successful completion of MindBio’s Phase 1 clinical trial, the MindBio team is now preparing for Phase 2 Clinical Trials and progressing its work with a strong focus towards commercialization,” said Frederick Pels, CEO of Blackhawk.
About Blackhawk Growth
Blackhawk is an investment holding company looking to create substantial value for its shareholders through the acquisition and development of high growth companies. It has focused its investments in the health, cannabis and cannabidiol industries in both Canada and the United States.
For further information please contact:
Frederick Pels, Chief Executive Officer
Cautionary Note Regarding Forward-Looking Statement
All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Company within the meaning of applicable securities laws, including with respect to transaction and future operations of MindBio Therapeutics Pty Ltd. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited those identified and reported in the Company’s public filings under the Company’s SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.
Copyright (c) 2022 TheNewswire - All rights reserved.